BACKGROUND:
The outcome of chemotherapy for pulmonary, extrapulmonary, and disseminated tuberculosis is not well documented, especially in developing countries. This study assessed tuberculosis treatment outcome, cureltoltreatment ratio and mortality among all types of tuberculosis patients in a tertiary care setting in Saudi Arabia. METHODS: All cases diagnosed and treated for active Mycobacterium tuberculosis infection between 1991 and 2000 were included retrospectively. Data collected included type of tuberculosis involvement, treatment outcome, relapse, and colmorbidities. RESULTS: Over a tenlyear period, 535 cases of tuberculosis were diagnosed and treated. Isolated pulmonary tuberculosis was identified in 141 cases (26.4%), extrapulmonary tuberculosis in 339 cases (63.3%), and coml l bined pulmonary and extrapulmonary disseminated involvements in 55 cases (10.3%). Colmorbidities were noted in 277 (52%) patients. Immunosuppression was found in 181 (34%) patients. The cure rate was 82%. The cureltoltreatment ratio was 86% in extrapulmonary tuberculosis and 78% in pulmonary tuberculosis, and 65% in disseminated tuberculosis. Overall mortality was 18%. Disseminated tuberculosis had the highest mortality (34.9%), followed by pulmonary (21.8%), then extrapulmonary tuberculosis (13.6%). Fortylseven percent of all mortalities were directly related to tuberculosis. Relapse was documented in 14 out of 349 patients (4%) who had 24 months of follow up. CONCLUSION: Despite tertiary care support, complicated tuberculosis carries a high mortality. Earlier diagnol l sis and complete appropriate chemotherapy are essential for improved outcome.
influenced by establishing an early diagnosis, initiating appropriate therapy, and adhering to and completing a treatment regimen. Relapse was frequent among pam m tients with pulmonary tuberculosis who had received incomplete treatment. 6 As relapse did not occur among patients who have had a full course of modern chemom m therapy, abolishing routine follow up was recommendm m ed. The rate of tuberculosis relapse is low for those who complete the treatment irrespective of the site of involvement. 7 Data on tuberculosis outcome, mortalm m ity, and relapse are limited in immunocompromised patients or patients with commorbid conditions from developing countries. In this study, we report treatment outcome and mortality and compare the cure, relapse, and tuberculosismrelated mortality for all pulmonary, extrapulmonary, and disseminated involvements at a tertiary care center.
METHODS
All cases of M. tuberculosis infection between 1991 and 2000 were identified from the databases of the Section of Infectious Diseases, Infection Control, and the Microbiology Laboratory. The outcome of all tum m berculosis cases diagnosed and treated at King Faisal Specialist Hospital and Research Center was assessed retrospectively. This 700mbed facility is the main nam m tional tertiary care referral center for cancer, cardiac, organ and bone marrow transplantation, and HIVm infected patients. Demographic, clinical, and outcome data were abstracted from medical records using a unim m form data collection form. Mortality data were assigned as tuberculosismrelated (patients died on treatment due to tuberculosis or its complications) or unrelated (pam m tients died due to medical conditions other than tuberm m culosis during or after treatment) by a single reviewing investigator. Cases were classified into extrapulmonary tuberculosis where organs other than the lungs were inm m volved by M. tuberculosis. If the lungs were also actively involved as evidenced clinically, radiologically, or microm m biologically, the condition was considered disseminated tuberculosis. Isolated pulmonary tuberculosis was conm m sidered if patients had evidence of tuberculosis involvm m ing the lungs only. All treatment courses were based on the guidelines of the National Tuberculosis Program, using four drugs. For pulmonary tuberculosis in immum m nocompetent patients, duration was for six months. For extrapulmonary tuberculosis in immunocompromised hosts, duration was extended to one year.
Terms used in this report are defined as follows: Treatment completion: record of treatment course completion was noted. Defaulters: record of loss of follow up, but no rem cord of treatment completion elsewhere. Transferred cases: transferred to another center but no treatment results available. Cure: record of cure after treatment completion, based on clinical, radiological, and microbiom logical evidence. Relapse: defined as remtreatment within 24 months after completing the initial first course of tum berculosis chemotherapy due to confirmed persistent disease clinically or microbiologim cally. Epi Info Version 6.04 (Centers for Disease Control and Prevention, Atlanta, GA and World Health Organization, Geneva, Switzerland) was used for data entry. Statistical analysis was performed using the Statistica Software Package Version 5.0 (StatSoft, Tulsa, OK). The Student' s t test was used to calculate continuous variables, and the chimsquare or Fisher' s exm m act test was used for proportions. All reported P values are twomtailed and a value of 0.05 was considered sigm m nificant.
RESULTS
Over the study period, 535 cases of tuberculosis were diagnosed and treated. Isolated pulmonary tuberculom m sis was identified in 141 cases (26.4%), extrapulmonary tuberculosis in 339 cases (63.3%), and both pulmonary and extrapulmonary disseminated involvements in 55 cases (10.3%). Table 1 summarizes the baseline data of all patients. All patients had microbiological and/or histopathological confirmation of tuberculosis except for 22 patients (4%) who were classified as having tum m berculosis based on clinical judgment and a favorable response to tuberculosis chemotherapy. Diagnosis was significantly delayed in patients with extrapulmonary tum m berculosis compared with patients with isolated pulmom m nary tuberculosis (7 weeks versus 4.3 weeks, P=0.003). Outcome data are summarized in Table 2 . Followmup, treatment, and outcome data were available for 401 pam m tients (75%). Of the 535 patients, care was transferred to other health care facilities in 57 cases (10.6%) and 77 patients (14.4%) defaulted. Commorbidities were noted in 277 patients (52%). The commonest was intentional immunosuppression therapy for organ transplantation, autoimmune diseases or neoplasia, which were noted in 181 (65.3%).
The overall cure rate for all tuberculosis cases that had followmup data and completed treatment was 329/401 (82%). The curemtomtreatment ratio was 79/101 (78%), 222/257 (86%), and 28/43 (65%) in the pulmonary, extrapulmonary, and disseminated tum m berculosis cases, respectively. Relapse was noted in 14 of 329 patients (4%) who had 24 months of follow up (pulmonary tuberculosis, 4.7%; extrapulmonary, 3.4%; and disseminated tuberculosis, 6.3%). Overall mortalm m ity was 72 of 401 (18%). The mortality rate in pulmom m nary tuberculosis was 22/101(21.8%), extrapulmonary, 35/257 (13.6%), and disseminated tuberculosis, 15/43 (34.9%). Mortality was directly related to tuberculosis in 34 patients (47%). The distribution of tuberculosis mortality for various forms of tuberculosis is presented in Table 3 .
DISCUSSION
Although completion of treatment for active cases of tuberculosis is the most important priority for tuberm m culosis control programs, reporting treatment success rate, mortality, and relapse should also be highlighted. The National Tuberculosis Program (NTP) targets and sets a cure rate of more than 85% of detected new cases of sputum smearmpositive tuberculosis. The NTP emphasizes curing as many patients as possible to reduce transmission of M. tuberculosis infection. A cure rate of at least 85% will decrease immediately the prevalence and the rate of transmission. The incidence will decrease gradually and there will be less acquired drug resistance. This in turn makes future treatment of tuberculosis easier and more affordable. Detecting the rate of defaulters will estimate roughly the threat of spreading resistant strains of mycobacteria. 8, 9 In this study, 52 of 196 patients (27%) who were potentially infectious (with pulmonary and disseminated type) had no reportable outcome. The majority of them dem m faulted treatment. We are reporting rates of cure less than the 85% that is recommended by World Health Organization, even when transferred cases and defaultm m ers were excluded. The curemtomtreatment ratio was 78% in the pulmonary and 65% in the disseminated type of infection.
The overall treatment success rate of all tuberculosis cases diagnosed between 1993 and 1999 from a tertiary care hospital in the western region of our country with a high prevalence of tuberculosis was 69.4% when pam m tients who were lost to followmup were excluded. 10 Such data are not only reflective of the tuberculosis treatment and control program, but also the competence of the health care system in identifying these cases, instituting appropriate treatment and successfully completing the course of chemotherapy.
The considerably high mortality rate among study cases may be related to the high population of patients with severe commorbid illnesses in whom the diagnosis was delayed. It indicates the significant impact of the disease in severely ill patients, or those who are requirm m ing corticosteroids. Such settings are associated with high mortality rates and low treatment success rates. 11m14 This hospital has been serving a large population of pam m tients with immunocompromised conditions as a referm m Table 1 . baseline data on the study population.
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ral hospital, transplantation, hematology/oncology and HIV treatment center. In fact, the study institute has been managing more extrapulmonary tuberculosis since its early days. 12m14 Worldwide, the casemfatality rate of smearmpositive pulmonary tuberculosis among persons on treatment is 3.8%. 15 There are limited data reporting treatment completion from the developing countries. The mortality among patients with pulmonary tubercum m losis in a teaching hospital in Ghana was associated with increased age and more prolonged symptom duration prior to therapy. 16 In the year 2000, WHO surveillance of tuberculosis treatment in Europe recorded a successm m ful outcome rate of 77%. 17 The tuberculosis treatment outcome in England in a district with high prevalence of disease was 88% for the curemtomtreatment completion ratio, 12% mortality, and a 1% relapse rate among 205 definite cases of pulmonary tuberculosis.
18 Multidrugm resistant tuberculosis (MDRmTB) was inversely associm m ated with a successful outcome. 17 In a referral hospital from Turkey, the tuberculosis treatment success rate between 1997 to 1999 was 71.9%. Failure was encounm m tered mainly among patients with rifampicin resistance and MDRmTB. 19 In our country outcome has never been reported on a large scale, including mortality and relapse. The future tracking of indicators of patient care such as delayed diagnosis and overall tuberculosismrelatm m ed mortality rate may offer better efficiency in resource utilization, special care for highmrisk patients and aid in the conduct of clinical trials.
At tuberculosis care facilities establishment of a management program is recommended as is evaluation of common predictors of outcome at presentation such as age, time from onset of symptoms to diagnosis, chest radiographic findings, culture and susceptibility results, smear status, HIV status, and the presence of associated commorbid illnesses. Drug resistance proved the most important factor affecting treatment outcome. Success rates in remtreatment of patients with MDRmTB are low. 19 Physicians and other health care providers must devote a great deal of their time and effort to avoiding late diagm m nosis, start treatment as soon as the clinical suspicion is high, track adherence with medications, defaulters, pam m tients transferred to other local units and make sure that patients with tuberculosis are adequately treated.
The limitation of this study is that it is from a single center and retrospective. The extrapulmonary tubercum m losis may have been influenced by the high rate of tum m berculous lymphadenitis, comprising around 40% of the cases. The early diagnosis, initiation and completion of appropriate treatment for tuberculosis have to be augm m mented by raising awareness among care providers. 
